Result
-€26,702 -€26,702
From profit to loss in 2024, after a profit of €33,610 in 2023.
PHARMAGILLY
Lifetime
19 annual accounts with figures on one time axis, 22 filings since 2003peak €157,275 (2021)
€120,224▼ 11.1%
lowest -€30,013 (2018)
-€26,702▼ €60,313
peak €215,307 (2023)
€188,605▼ 12.4%
€528,420▼ 8.6%
peak 3.2 FTE (2006)
1.3 FTE
Board8 names since 2016
1 director
Owners
Documentsfilings and deeds
25-09-202556 days late
2024financial year
Loss of €26,702Equity from €215,307 to €188,605Cash from €46,650 to €5,106
Key points
from the 2024 annual accountsTurnover
≈ €560,000 estimated
The accounts state no turnover.
Debts
€528,420 74% of the balance sheet
Financial debts 66%Suppliers 6%Taxes and wages 5%Other 22%
€397,508 of the debts are secured on the company's own assets.
Staff
1 employees on 31-12-2024
In 2024, 4 people joined and 4 left.
Filings
22 annual accounts 105 days past the deadline
2025 accounts not filed: deadline was 31-07-2026.
Position in the sector
-€26,702
Lower net result than 84% of companies in retail trade. Sector median €32,436 · 6,426 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 2,453 companies had the same profile as PHARMAGILLY has now. Each dot stands for 7 companies, two years later.
93.1%
were still trading
5.1%
stopped another way
1.5%
went bankrupt
Another 0.3% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 2,453 companies, not a prediction for PHARMAGILLY. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Board and ownership
Director, , since 22-12-2016
- 99.33%equity €2.0m (2023) · 2023 annual accounts of
- annual accounts 2024
Recent changes
Judicial dissolution, liquidator appointed
Enterprise Court of Hainaut, Charleroi division · Schreder Philippe-Robert · judgment of 19-06-2023 · Bankruptcy
2 directors appointed, 6 resignations
Resignations: , , , , and · Appointments: and · Permanent representative: · General meeting of 22-12-2016 · Gazette deed
Incorporation
published on 28-07-2003 · Gazette deed
First establishment
Chaussée de Châtelet 274, Charleroi
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMAGILLY Charleroi | €717,024 | €120,224 | 26.3% | 1.3 |
| SENNE PHARMA Soignies | €617,578 | €126,239 | 32.0% | 1.5 |
| PHARMACIE CORNIL Ath | €784,819 | €153,026 | 75.6% | 1.5 |
| APOTHEEK op OVERSCHELDE Wetteren | €745,559 | €138,865 | 74.8% | 1.5 |
| UNIPHARM Veurne | €716,027 | €128,221 | 51.6% | 1.5 |
| Pharmadons Ixelles | €608,875 | €110,101 | 16.1% | 1.3 |
| DEMAPHARMA Ottignies-Louvain-la-Neuve | €659,253 | €122,780 | 58.5% | 1 |
These companies have the same main activity as PHARMAGILLY: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €609,000 and €785,000, founded between 2002 and 2007.
Official details
Source: KBO- Status
- Active since 18-07-2003Normal situation
- Activity
- Retail sale of pharmaceutical productsNACE 47730
- Joint committee
- 313Pharmacies and pricing offices · annual accounts 2024
- Establishment unit
- 2.230.928.7346060 Charleroi, since 18-07-2003
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Insights on PHARMAGILLY
PHARMAGILLY has existed since 2003. The gross margin grew from €78,568 in 2006 to €120,224 in 2024, while staff fell from 3.2 to 1.3 full-time equivalents.
holds 99.33% of the shares.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMAGILLY
- What is the company number of PHARMAGILLY?
- The company number of PHARMAGILLY is 0859.702.882. The VAT number is the same number with BE in front: BE 0859.702.882.
- Where is PHARMAGILLY based?
- The registered office is at Chaussée de Châtelet 274, 6060 Charleroi.Company details
- What does PHARMAGILLY do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of PHARMAGILLY?
- PHARMAGILLY is a public limited company (NV).
- When was PHARMAGILLY founded?
- PHARMAGILLY was founded on 18-07-2003.
- Is PHARMAGILLY still active?
- Yes, PHARMAGILLY is an active enterprise in the KBO register.
- How many employees does PHARMAGILLY have?
- PHARMAGILLY had an average of 1.3 full-time equivalents in financial year 2024, according to the filed annual accounts.Financials
- Which joint committee does PHARMAGILLY fall under?
- In its 2024 annual accounts, PHARMAGILLY states joint committee 313 (Pharmacies and pricing offices).
- What is the turnover of PHARMAGILLY?
- The turnover in financial year 2024 is ≈ €560,000. This figure is estimated from the gross margin of €120,224 and 52 comparable companies (NACE 477). It probably lies between €380,000 and €1.1m.
- Is PHARMAGILLY profitable?
- In financial year 2024, PHARMAGILLY made a loss of €26,702.
- Where can I find the annual accounts of PHARMAGILLY?
- PHARMAGILLY filed 22 annual accounts with the National Bank of Belgium, the latest for financial year 2024.
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.